Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 3
Opinion
Video
Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma
Author(s):
An expert discusses the detection of circulating tumor DNA (ctDNA) prior to surgery, noting higher detection rates in stage III patients compared with stage IIB/C patients, and its significant association with a greater number of involved lymph nodes, extracapsular extension, and clinically evident disease, while also highlighting that all 6 patients with ctDNA detected during the surveillance period developed recurrent melanoma. The expert also provides an overview of the 40-gene expression profile (GEP) test for squamous cell carcinoma (SCC) risk stratification and discusses its utility.
Video content above is prompted by the following:
- Detection of ctDNA prior to surgery was higher in stage III patients than in stage IIB/C patient and was also significantly associated with a greater number of involved lymph nodes, extracapsular extension, and clinically evident disease.
- Of the 6 patients who had ctDNA detected during the surveillance period, all developed recurrent melanoma.
- A 40-GEP test has also been developed for the stratification of SCC patient risk. Could you provide an overview and discuss the utility of the test?
Related Videos
Related Content
